Wanbury Limited
All news and filings related to Wanbury Limited.
View all news & filings- Medium impact
Wanbury Files New DMF in South Africa, Expands API Reach
Wanbury Limited has filed a new Drug Master File (DMF) in South Africa for Tramadol HCl API. The company also filed DMFs in the Philippines and Singapore for Metformin HCl API. Additionally, EDQM has approved compliance reports for Paroxetine HCl API, enabling continued supply to Australia.
Read the summary - Low impact
Wanbury Limited: Trading Window Closed for Q2 FY27 Results Until Post-Declaration
Wanbury Limited's trading window for securities is closed from October 1, 2026. It will reopen 48 hours after the declaration of the unaudited financial results for the quarter and half-year ended September 30, 2026. The board meeting date for results declaration will be announced later.
Read the summary - Medium impact
Wanbury Ltd's 38th AGM: All 4 Resolutions Passed with High Shareholder Approval
Wanbury Limited's 38th AGM on September 24, 2026, passed all four resolutions. Key approvals included the adoption of FY26 financial statements, re-appointment of Director K. Chandran, ratification of Cost Auditor remuneration, and re-appointment of Whole-time Director Mohan Kumar Rayana.
Read the summary - Low impact
Wanbury Limited: AGM Approves Cost Auditor Remuneration & Re-appoints Whole-time Director
Wanbury Limited's 38th AGM on September 24, 2026, approved the appointment of M/s. ABK & Associates as Cost Auditor for FY2026-27. It also re-appointed Mr. Mohan Kumar Rayana as Whole-time Director from August 21, 2026, to August 20, 2031, continuing his service beyond age 70.
Read the summary - Low impact
Wanbury Limited Holds 38th AGM on Sep 24, 2026; All Resolutions Passed
Wanbury Limited's 38th AGM was held on September 24, 2026. All resolutions, including the adoption of FY26 financial statements and director re-appointments, were passed. Mr. K. Chandran presided, and Mr. Mohan Kumar Rayana was re-appointed as Whole-time Director.
Read the summary - Low impact
Wanbury Limited announces 38th AGM on Sep 24, 2026, via VC/OAVM
Wanbury Limited will hold its 38th Annual General Meeting on September 24, 2026. The meeting will be conducted via Video Conferencing (VC) / Other Audio Visual Means (OAVM). This announcement was published in newspapers on September 2, 2026.
Read the summary - Low impact
Wanbury Limited Announces Book Closure for 38th AGM on Sep 24, 2026
Wanbury Limited will hold its 38th Annual General Meeting on September 24, 2026. The company's Register of Members and Share Transfer Books will be closed from September 18 to September 24, 2026, for the AGM.
Read the summary - Medium impact
Wanbury Limited Announces 38th AGM on Sep 24, 2026, to Discuss Annual Report & Director Re-appointment
Wanbury Limited will hold its 38th AGM on September 24, 2026, via VC/OAVM. Key agenda items include adopting the FY26 annual report, re-appointing director Mr. K. Chandran, and ratifying cost auditor M/s. ABK & Associates' remuneration of ₹4 Lakhs for FY27. The re-appointment of Mr. Mohan Kumar Rayana as Whole-time Director for five years from August 21, 2026, will also be discussed.
Read the summary - Low impact
Wanbury Ltd: 38th AGM on Sep 24, 2026, via VC/OAVM
Wanbury Limited will hold its 38th Annual General Meeting on September 24, 2026, at 11:30 a.m. IST via Video Conferencing/Other Audio Visual Means. The announcement was published in newspapers on August 28, 2026.
Read the summary - Medium impact
Wanbury Ltd Secures EDQM Approval for Rivaroxaban API, USFDA DMF Clearances
Wanbury Limited received EDQM approval for Rivaroxaban API, enabling supply to EU countries. The company also obtained USFDA DMF clearance for Paraxetine HCI and Metformin HCI, and is undergoing ANDA reviews for multiple customers.
Read the summary - Medium impact
Wanbury Q1 FY27 Revenue Up 1.5% to ₹165.6 Cr Amidst Margin Pressure
Wanbury Limited reported Q1 FY27 revenue of ₹165.6 crore, up 1.5% YoY. Margins were impacted by rising raw material costs and logistics disruptions. The company completed a ₹205 crore debt refinancing, lowering borrowing costs to sub-10% and releasing promoter shareholding pledges. Regulatory inspections were cleared in Australia and Korea, with USFDA also issuing a 'No DME deficiency letter'.
Read the summary - Medium impact
Wanbury Board Approves Q1 FY27 Results; Re-appoints Mohan Kumar Rayana
Wanbury Limited reported Q1 FY27 revenue from operations of ₹16,558.35 Lakhs. The Board approved the allotment of 27,530 equity shares under its ESOP plan and re-appointed Mr. Mohan Kumar Rayana as Whole-time Director for five years from August 21, 2026. The company also secured ₹205 crore in borrowings.
Read the summary - Medium impact
Wanbury Receives USFDA No DMF Deficiency Letter for Metformin HCl API ANDAs
Wanbury Limited received a "No DMF deficiency letter" from the USFDA for multiple ANDAs related to its Metformin HCl API. This positive regulatory development supports the company's API offerings. Wanbury is also expanding into new markets, having filed a DMF for another API in South Korea.
Read the summary - Medium impact
Wanbury Limited's Tanuku Facility Receives 6 Observations from USFDA Inspection
Wanbury Limited's Tanuku facility was inspected by the USFDA from July 13-17, 2026. The inspection resulted in six observations on a Form 483. The company will respond within the stipulated time and anticipates no material impact on operations or financial performance.
Read the summary - Medium impact
Wanbury Limited's Tanuku Facility Receives 6 Observations from USFDA Inspection
Wanbury Limited's facility in Tanuku underwent a USFDA inspection from July 13-17, 2026. The inspection resulted in a Form 483 with six observations. The company will respond to the FDA within the stipulated time.
Read the summary - Low impact
Wanbury Limited Clarifies Price Surge, Cites Market Driven Factors
Wanbury Limited has clarified a significant price movement in its stock, stating that all material information has been previously disclosed. The company confirmed no new material events require disclosure and attributed the price surge to market-driven factors. Wanbury will continue to comply with all regulatory disclosure requirements.
Read the summary - Medium impact
Wanbury Limited announces early redemption of NCDs worth ₹180 crore
Wanbury Limited's Board approved the early redemption of 12.5% unlisted NCDs. The principal amount outstanding is ₹180 crore, part of an initial ₹200 crore issue. The redemption date is to be finalized on or before the original maturity of February 28, 2030, with a record date of June 20, 2026.
Read the summary - Low impact
Expert Chemicals Declares No Encumbrance for FY26 Under SEBI Takeover Regulations
Expert Chemicals (India) Private Limited, a promoter of Wanbury Limited, declared no new encumbrances on shares during the financial year ended March 31, 2026. This filing adheres to SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Read the summary - Medium impact
Wanbury's Tanuku API site passes TGA quality inspection; Korean FDA GMP cert received
Wanbury Limited's Tanuku API manufacturing site successfully passed a quality inspection by Australia's TGA. This enables the shipment of three additional APIs upon receiving the GMP certificate. Additionally, the Patalganga site received a GMP certificate from the Korean FDA.
Read the summary - Low impact
Wanbury Limited Schedules Analyst & Investor Meetings on June 5, 2026
Wanbury Limited will host an investor and analyst meeting on June 5, 2026, including a site visit. Discussions will focus on past financial results and public information. The schedule may be subject to change.
Read the summary - High impact
Wanbury FY26 PAT Surges 117% YoY to ₹66.1 Cr; EPS Doubles to ₹20.55
Wanbury Limited reported FY26 PAT surge of 117% YoY to ₹66.1 Cr and EPS doubling to ₹20.55. EBITDA grew 34.9% YoY to ₹107.7 Cr. The company launched a new Anaesthetic API and received zero observation from MFDS, Korea inspection. Q4 FY26 PAT grew 7.2% YoY to ₹21.7 Cr.
Read the summary - Low impact
Wanbury Limited Reports Audited Financial Results for FY26
Wanbury Limited announced its audited financial results for the quarter and year ended March 31, 2026. The Board of Directors approved the results and the auditor's report, which received an unmodified opinion. The board meeting concluded on May 29, 2026.
Read the summary - Medium impact
Wanbury Limited's Patalganga site receives Zero Observation from Korea FDA.
Wanbury Limited's Patalganga facility successfully passed a regulatory inspection by the Korea FDA with zero observations, confirming cGMP compliance. This follows previous zero-observation approvals from USFDA and Anvisa for its manufacturing sites. The company is also expanding its API manufacturing capabilities.
Read the summary - Low impact
Wanbury Limited: Secretarial Compliance Report for FY ended March 31, 2026
Wanbury Limited's Secretarial Compliance Report for FY 2025-26 confirms adherence to SEBI regulations. A delay in submitting the Q2 FY26 Shareholding Pattern resulted in a ₹42,480 fine paid on Nov 27, 2025. The company has addressed previous observations regarding promoter holdings, board composition, and committee requirements.
Read the summary - Low impact
Wanbury Ltd. Submits SEBI Compliance Certificate for Q4 FY26
Wanbury Limited submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended March 31, 2026. The RTA confirmed processing of dematerialized securities and cancellation of physical certificates. Details of specific share dematerialization transactions for the quarter are also provided.
Read the summary - Low impact
Wanbury Limited Closes Trading Window for Financial Results Announcement
Wanbury Limited will keep its trading window closed from April 1, 2026, until 48 hours after the declaration of its audited financial results for the quarter and year ended March 31, 2026. The exact date for the board meeting to announce these results will be communicated later.
Read the summary - Medium impact
Wanbury Launches New Pediatric Cold & Sneezing Products for Coriminic Brand
Wanbury Limited has launched Coriminic CPM Drops and Coriminic NS Nasal Drops to strengthen its Coriminic brand for pediatric use. These launches align with DCGI regulations restricting fixed-dose cold combinations for children under 4. The move aims to capture a share of the ₹861 crore Cold Preparation Liquid market.
Read the summary - High impact
Wanbury Ltd. Secures Sertraline Form II Approval in Brazil; Metformin Business Opportunity Worth ₹15 Cr/Annum
Wanbury Limited received Sertraline Form II approval from ANVISA, Brazil, aiming to further consolidate its 75% market share. The company also secured approval for a special grade of metformin DC grade from a large customer, with an estimated annual business opportunity of ₹15 crore. Manufacturing sites remain cGMP compliant.
Read the summary - Medium impact
Wanbury Ltd Presents Investor Deck for Q3 & 9MFY26 Results
Wanbury Limited reported a 22% YoY revenue growth in Q3FY26 and 14% in 9MFY26. EBITDA surged 91% YoY in Q3 and 65% in 9MFY26, driven by operational efficiencies and new product launches. The API business commissioned a new production block for an anaesthetic product. The Formulations business turned EBITDA positive.
Read the summary - Medium impact
Wanbury Board Approves Q3 Unaudited Results & ESOP Grants
Wanbury Limited announced its unaudited Q3 FY26 results. The company approved the grant of 60,000 ESOPs and allotted 47,400 equity shares upon exercise of options. A dividend payment was also approved, details of which are provided in the announcement.
Read the summary - Medium impact
Wanbury Ltd Board Approves Q3 FY26 Results, Grants 60,000 ESOPs, Declares Dividend
Wanbury Limited reported Q3 FY26 results with revenue at ₹162.62 crore. The Board approved the grant of 60,000 ESOPs and allotted 47,400 equity shares upon exercise of options. A dividend of ₹19.05 per share was declared.
Read the summary - Medium impact
Wanbury Ltd. achieves first sales invoicing for new anesthetic API product
Wanbury Limited achieved its first sales invoicing for a new anesthetic API product on January 30, 2026. The company completed its first commercial shipment to a European customer from its Tanuku facility. This milestone is expected to drive significant growth and market leadership.
Read the summary - High impact
Wanbury Launches Key API Products in FY27, Targeting ₹100 Crore Revenue
Wanbury Limited announced the launch of key API products at its Tanuku facility, targeting ₹100 crore plus incremental revenue in FY 2026-27. The company is introducing four high-value APIs: Antidiabetic, Anticoagulant, Antidepressant, and Anti Tussive molecules. The Tanuku facility is expected to be ready by March 2026.
Read the summary - Low impact
Wanbury Limited submits SEBI compliance certificate for Q3 FY26
Wanbury Limited submitted a compliance certificate for Q3 FY26 from its RTA, Purva Sharegistry. The certificate confirms dematerialisation of securities for the quarter ended December 31, 2025, and adherence to SEBI regulations. Details of dematerialised shares from October to December 2025 are provided.
Read the summary - Medium impact
Wanbury Ltd: EOGM Approves Re-appointment of Manojkumar Gursahani as Director
Wanbury Limited's EOGM on January 5, 2026, approved the re-appointment of Mr. Manojkumar Khubchand Gursahani as Non-Executive Independent Director. The resolution passed with 99.99% of valid votes in favor.
Read the summary - Low impact
Wanbury Re-appoints Manojkumar Khubchand Gursahani as Non-Executive Independent Director
Wanbury Limited's members approved the re-appointment of Mr. Manojkumar Khubchand Gursahani as Non-Executive Independent Director. He will serve for a one-year term from January 8, 2026, to January 7, 2027. Mr. Gursahani holds a commerce graduate degree and has no disqualifications.
Read the summary - Low impact
Wanbury Ltd Holds EOGM on Jan 5, 2026, for Director Re-appointment
Wanbury Limited held an EOGM on January 5, 2026, via video conference. Key business included the re-appointment of Mr. Manoj K. Gursahani as Non-executive Independent Director. Remote e-voting was available from January 2-4, 2026. E-voting results are expected by January 7, 2026.
Read the summary - Low impact
Wanbury Limited: Trading Window Closed for Q3 FY26 Results
Wanbury Limited's trading window is closed from January 1, 2026, until 48 hours after the declaration of Q3 FY26 results. This applies to designated persons and their relatives.
Read the summary - Low impact
Wanbury Limited Announces EGM on Jan 5, 2026 via VC/OAVM
Wanbury Limited will hold its Extra Ordinary General Meeting (EGM) on January 5, 2026, at 3:00 PM. The meeting will be conducted via Video Conference (VC) or Other Audio Visual Means (OAVM). This was announced through newspaper publications on December 13, 2025.
Read the summary - Low impact
Wanbury Limited Announces EOGM on Jan 5, 2026; Book Closure Dec 30, 2025 - Jan 5, 2026
Wanbury Limited will hold its Extra-Ordinary General Meeting (EOGM) on January 5, 2026. The company's Register of Members and Share Transfer Books will be closed from December 30, 2025, to January 5, 2026, for this purpose.
Read the summary - Low impact
Wanbury Limited Announces EOGM on Jan 5, 2026, for Director Re-appointment
Wanbury Limited will hold an Extra-Ordinary General Meeting (EOGM) on January 5, 2026, to re-appoint Mr. Manojkumar Khubchand Gursahani as Non-Executive Independent Director for a one-year term starting January 8, 2026. Shareholders can participate and vote remotely via e-voting from January 2 to January 4, 2026.
Read the summary - Low impact
Wanbury Limited Announces EGM on January 5, 2026, via VC/OAVM
Wanbury Limited will hold an Extra-Ordinary General Meeting (EGM) on January 5, 2026, at 3:00 PM IST via Video Conference/OAVM. The announcement was published in newspapers on December 11, 2025.
Read the summary - Low impact
Wanbury Limited Board Approves Re-appointment of Independent Director; EGM on Jan 05, 2026
Wanbury Limited's Board approved the re-appointment of Mr. Manojkumar Khubchand Gursahani as Non-Executive Independent Director for one year from Jan 08, 2026. An EGM is scheduled for January 05, 2026, to seek shareholder approval.
Read the summary - Medium impact
Wanbury Investor Presentation on Q2 & H1FY26 Financial Results
Wanbury Limited announced its investor presentation on Q2 & H1FY26 financial results, highlighting EBITDA growth, reduced borrowing costs, and a focus on regulated markets and new molecule launches.
Read the summary - Medium impact
Wanbury Limited Announces Investor Presentation for Q2 & H1FY26
Wanbury Limited announced its investor presentation for Q2 & H1FY26, highlighting financial performance, business strategy, and future plans. Key financials include revenue of ₹323.2 crore, EBITDA of ₹50.77 crore and PAT of ₹28.67 crore.
Read the summary - High impact
Wanbury reports robust Q2 & H1 FY26 results with 216.6% YoY PAT jump to ₹28.7 crore
Wanbury reports strong Q2 & H1 FY26 financial results with a 216.6% YoY PAT jump to ₹28.7 crore, driven by volume growth, cost efficiencies, and improved product yield.
Read the summary - High impact
Wanbury reports strong Q2 FY26 results, approves ESOP share allotment
Wanbury Limited's Board approved strong Q2 FY26 financial results with increased profit and EPS. The company also allotted 15,000 ESOP equity shares, increasing its paid-up share capital.
Read the summary - Low impact
Wanbury Limited Approves Unaudited Financial Results for Q2 & H1 Ended Sept 30, 2025, and ESOP Allotment
Wanbury Limited approved unaudited financial results for Q2 & H1 ended Sept 30, 2025, and allotted 15,000 equity shares under ESOP 2016, increasing the paid-up share capital to ₹34,89,19,980.
Read the summary - Low impact
Wanbury Limited Allots NCDs worth ₹25 Crore to Tata Capital
Wanbury Limited allots 250 NCDs worth ₹25 Crore to Tata Capital Limited on private placement basis for capital expenditure and working capital, with 12.5% interest rate, maturing on February 28, 2030.
Read the summary - Low impact
Wanbury Limited files Certificate under SEBI (Depositories and Participants) Regulations, 2018
Wanbury Limited filed a certificate from its RTA, Purva Sharegistry, under SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2025, confirming dematerialization compliance.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio - Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio - Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio